Xiangxue Pharmaceutical

Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis

Retrieved on: 
Monday, September 27, 2021

BUFFALO, N.Y., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced today that its partner, Almirall (Almirall, S.A., BME: ALM), has launched Klisyri® (tirbanibulin) in Germany and the UK. Klisyri received approval by the European Commission and the UK Medicines & Healthcare products Regulatory Agency (MHRA) in July and August of 2021, respectively, for the topical treatment of actinic keratosis (AK) of the face and scalp in adults.

Key Points: 
  • Klisyri received approval by the European Commission and the UK Medicines & Healthcare products Regulatory Agency (MHRA) in July and August of 2021, respectively, for the topical treatment of actinic keratosis (AK) of the face and scalp in adults.
  • We are extremely pleased to see Klisyri launching in these two major European markets by our partner Almirall, said Dr. Johnson Lau, Chief Executive Officer of Athenex.
  • The launch of Klisyri represents an option with acceptable tolerability and shorter duration of treatment for dermatologists to provide their patients.
  • Klisyri (tirbanibulin) is a microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) of the face or scalp.

111 to be the Omni-channel Drug Commercialization Partner of Xiangxu Pharmaceutical for Traditional Chinese Medicine

Retrieved on: 
Thursday, October 15, 2020

Per the Agreement, 111 will become an omni-channel commercialization partner of Xiangxue Pharmaceutical.

Key Points: 
  • Per the Agreement, 111 will become an omni-channel commercialization partner of Xiangxue Pharmaceutical.
  • The Agreement aims to combine the strength of 111's omni-channel drug commercialization platform and Xiangxue Pharmaceutical's expansive portfolio of products to drive the growth of traditional Chinese medicine.
  • Xiangxue Pharmaceutical is specialized in the health industry, covering fields such as traditional Chinese medicine decoction pieces, Chinese patent medicine, functional healthcare products, biomedical engineering, and life science research.
  • The company has become a leading traditional Chinese medicine modernization company with proprietary intellectual property rights, its brands and self-dependent innovation ability.

Athenex Announces Initiation of Phase I Clinical Study in China of KX2-361 Oral by Partner Guangzhou Xiangxue Pharmaceutical

Retrieved on: 
Wednesday, September 11, 2019

KX2-361 is a potentially valuable treatment option for GBM patients, and we are initiating this Phase I study on the strength of encouraging results in preclinical studies, stated Mr. YongHui Wang, Chairman of Xiangxue Pharmaceutical.

Key Points: 
  • KX2-361 is a potentially valuable treatment option for GBM patients, and we are initiating this Phase I study on the strength of encouraging results in preclinical studies, stated Mr. YongHui Wang, Chairman of Xiangxue Pharmaceutical.
  • We are excited to advance this promising candidate in the clinic to potentially improve the lives of patients with GBM.
  • In 2012, Athenex out-licensed KX2-361 to Xiangxue Pharmaceutical for development and marketing in Greater China and Singapore.
  • In May 2017, the China National Medical Products Administration (NMPA) (formerly China FDA) allowed Xiangxues IND to commence clinical trials of KX2-361 in China.